Brain activation predicts treatment improvement in patients with major depressive disorder

Andrea C. Samson, Eva Meisenzahl, Johanna Scheuerecker, Emma Rose, Veronika Schoepf, Martin Wiesmann, Thomas Frodl

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is associated with alterations in brain function that might be useful for therapy evaluation. The current study aimed to identify predictors for therapy improvement and to track functional brain changes during therapy. Twenty-one drug-free patients with MDD underwent functional MRI twice during performance of an emotional perception task: once before and once after 4 weeks of antidepressant treatment (mirtazapine or venlafaxine). Twelve healthy controls were investigated once with the same methods. A significant difference between groups was a relative greater activation of the right dorsolateral prefrontal cortex (dlPFC) in the patients vs. controls. Before treatment, patients responding better to pharmacological treatment showed greater activation in the dorsomedial PFC (dmPFC), posterior cingulate cortex (pCC) and superior frontal gyrus (SFG) when viewing of negative emotional pictures was compared with the resting condition. Activations in the caudate nucleus and insula contrasted for emotional compared to neutral stimuli were also associated with successful treatment. Responders had also significantly higher levels of activation, compared to non-responders, in a range of other brain regions. Brain activation related to treatment success might be related to altered self-referential processes and a differential response to external emotional stimuli, suggesting differences in the processing of emotionally salient stimuli between those who are likely to respond to pharmacological treatment and those who will not. The present investigation suggests the pCC, dmPFC, SFG, caudate nucleus and insula may have a key role as a biological marker for treatment response and predictor for therapeutic success.

Original languageEnglish (US)
Pages (from-to)1214-1222
Number of pages9
JournalJournal of Psychiatric Research
Volume45
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

Major Depressive Disorder
Brain
Prefrontal Cortex
Therapeutics
Caudate Nucleus
Gyrus Cinguli
Pharmacology
Antidepressive Agents
Biomarkers
Magnetic Resonance Imaging

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Samson, Andrea C. ; Meisenzahl, Eva ; Scheuerecker, Johanna ; Rose, Emma ; Schoepf, Veronika ; Wiesmann, Martin ; Frodl, Thomas. / Brain activation predicts treatment improvement in patients with major depressive disorder. In: Journal of Psychiatric Research. 2011 ; Vol. 45, No. 9. pp. 1214-1222.
@article{3f9332890bad4693bc0c2e00ccb1ae86,
title = "Brain activation predicts treatment improvement in patients with major depressive disorder",
abstract = "Major depressive disorder (MDD) is associated with alterations in brain function that might be useful for therapy evaluation. The current study aimed to identify predictors for therapy improvement and to track functional brain changes during therapy. Twenty-one drug-free patients with MDD underwent functional MRI twice during performance of an emotional perception task: once before and once after 4 weeks of antidepressant treatment (mirtazapine or venlafaxine). Twelve healthy controls were investigated once with the same methods. A significant difference between groups was a relative greater activation of the right dorsolateral prefrontal cortex (dlPFC) in the patients vs. controls. Before treatment, patients responding better to pharmacological treatment showed greater activation in the dorsomedial PFC (dmPFC), posterior cingulate cortex (pCC) and superior frontal gyrus (SFG) when viewing of negative emotional pictures was compared with the resting condition. Activations in the caudate nucleus and insula contrasted for emotional compared to neutral stimuli were also associated with successful treatment. Responders had also significantly higher levels of activation, compared to non-responders, in a range of other brain regions. Brain activation related to treatment success might be related to altered self-referential processes and a differential response to external emotional stimuli, suggesting differences in the processing of emotionally salient stimuli between those who are likely to respond to pharmacological treatment and those who will not. The present investigation suggests the pCC, dmPFC, SFG, caudate nucleus and insula may have a key role as a biological marker for treatment response and predictor for therapeutic success.",
author = "Samson, {Andrea C.} and Eva Meisenzahl and Johanna Scheuerecker and Emma Rose and Veronika Schoepf and Martin Wiesmann and Thomas Frodl",
year = "2011",
month = "9",
doi = "10.1016/j.jpsychires.2011.03.009",
language = "English (US)",
volume = "45",
pages = "1214--1222",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "9",

}

Samson, AC, Meisenzahl, E, Scheuerecker, J, Rose, E, Schoepf, V, Wiesmann, M & Frodl, T 2011, 'Brain activation predicts treatment improvement in patients with major depressive disorder', Journal of Psychiatric Research, vol. 45, no. 9, pp. 1214-1222. https://doi.org/10.1016/j.jpsychires.2011.03.009

Brain activation predicts treatment improvement in patients with major depressive disorder. / Samson, Andrea C.; Meisenzahl, Eva; Scheuerecker, Johanna; Rose, Emma; Schoepf, Veronika; Wiesmann, Martin; Frodl, Thomas.

In: Journal of Psychiatric Research, Vol. 45, No. 9, 09.2011, p. 1214-1222.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brain activation predicts treatment improvement in patients with major depressive disorder

AU - Samson, Andrea C.

AU - Meisenzahl, Eva

AU - Scheuerecker, Johanna

AU - Rose, Emma

AU - Schoepf, Veronika

AU - Wiesmann, Martin

AU - Frodl, Thomas

PY - 2011/9

Y1 - 2011/9

N2 - Major depressive disorder (MDD) is associated with alterations in brain function that might be useful for therapy evaluation. The current study aimed to identify predictors for therapy improvement and to track functional brain changes during therapy. Twenty-one drug-free patients with MDD underwent functional MRI twice during performance of an emotional perception task: once before and once after 4 weeks of antidepressant treatment (mirtazapine or venlafaxine). Twelve healthy controls were investigated once with the same methods. A significant difference between groups was a relative greater activation of the right dorsolateral prefrontal cortex (dlPFC) in the patients vs. controls. Before treatment, patients responding better to pharmacological treatment showed greater activation in the dorsomedial PFC (dmPFC), posterior cingulate cortex (pCC) and superior frontal gyrus (SFG) when viewing of negative emotional pictures was compared with the resting condition. Activations in the caudate nucleus and insula contrasted for emotional compared to neutral stimuli were also associated with successful treatment. Responders had also significantly higher levels of activation, compared to non-responders, in a range of other brain regions. Brain activation related to treatment success might be related to altered self-referential processes and a differential response to external emotional stimuli, suggesting differences in the processing of emotionally salient stimuli between those who are likely to respond to pharmacological treatment and those who will not. The present investigation suggests the pCC, dmPFC, SFG, caudate nucleus and insula may have a key role as a biological marker for treatment response and predictor for therapeutic success.

AB - Major depressive disorder (MDD) is associated with alterations in brain function that might be useful for therapy evaluation. The current study aimed to identify predictors for therapy improvement and to track functional brain changes during therapy. Twenty-one drug-free patients with MDD underwent functional MRI twice during performance of an emotional perception task: once before and once after 4 weeks of antidepressant treatment (mirtazapine or venlafaxine). Twelve healthy controls were investigated once with the same methods. A significant difference between groups was a relative greater activation of the right dorsolateral prefrontal cortex (dlPFC) in the patients vs. controls. Before treatment, patients responding better to pharmacological treatment showed greater activation in the dorsomedial PFC (dmPFC), posterior cingulate cortex (pCC) and superior frontal gyrus (SFG) when viewing of negative emotional pictures was compared with the resting condition. Activations in the caudate nucleus and insula contrasted for emotional compared to neutral stimuli were also associated with successful treatment. Responders had also significantly higher levels of activation, compared to non-responders, in a range of other brain regions. Brain activation related to treatment success might be related to altered self-referential processes and a differential response to external emotional stimuli, suggesting differences in the processing of emotionally salient stimuli between those who are likely to respond to pharmacological treatment and those who will not. The present investigation suggests the pCC, dmPFC, SFG, caudate nucleus and insula may have a key role as a biological marker for treatment response and predictor for therapeutic success.

UR - http://www.scopus.com/inward/record.url?scp=80051673177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051673177&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2011.03.009

DO - 10.1016/j.jpsychires.2011.03.009

M3 - Article

C2 - 21477817

AN - SCOPUS:80051673177

VL - 45

SP - 1214

EP - 1222

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 9

ER -